Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background: Riluzole is a glutamate regulator and effective in treatment of neuropsychiatric conditions. Aims: We assessed riluzole for treatment of methamphetamine dependence. Methods: In this randomized, double-blind, placebo-controlled clinical trial, male outpatients with methamphetamine dependence who were 18–65 years old received either 50 mg riluzole ( n=34) or placebo ( n=54) twice daily for 12 weeks. Patients were excluded in case of comorbid serious medical conditions or neurologic disorders, comorbid psychiatric disorders other than methamphetamine dependence requiring specific treatment interventions, simultaneous positive urine test result for substances of abuse other than methamphetamine, smoking >3 days per week, simultaneous consumption of medications which are contraindicated or have interaction with riluzole. Results: Concerning primary outcomes, the cumulative mean number of attended weekly visits was higher in the riluzole arm compared with the placebo arm approaching a statistically significant difference (riluzole, median (range)=13.00 (2.00–13.00); placebo=4.00 (2.00–13.00); Mann-Whitney U=505.00, p-value=0.073), and the weekly measured rate of positive methamphetamine urine test results was significantly lower in the riluzole arm by the end of the study (riluzole=1 (5.00%), placebo=9 (45.00%), p-value=0.004). Patients in the riluzole arm experienced significantly greater improvement on all the craving, withdrawal, and depression measures regarding mean score changes from baseline to endpoint. No significant difference was detected between the two arms in terms of incidence of adverse events. Conclusion: Future randomized clinical trials are needed to investigate proper dosing strategy in a more inclusive sample.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Ferrari, A. J., Degenhardt, L., Feigin, V., & Vos, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116820 · Cited by 1,175
The nature, time course and severity of methamphetamine withdrawal
McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01160.x · Cited by 458 · cited 3×
“According to calculation of Cohen’s d for mean difference in score changes between the two study arms, the highest effect size was observed for ASSA followed by AWQ, VAS, STCQ, and HAM-D, respectively.”
MethodMethamphetamine use: A comprehensive review of molecular, preclinical and clinical findings
Panenka, W. J., Procyshyn, R. M., Lecomte, T., MacEwan, G. W., Flynn, S. W., Honer, W. G., & Barr, A. M. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.016 · Cited by 432 · cited 1×
“Early mental effects of methamphetamine use include a sense of alertness, high energy, and well-being, followed by long-term cognitive impairment and mood/anxiety disturbances, in particular depression, during dependence and withdrawal (Panenka et al., 2013).”
BackgroundAshok, A. H., Mizuno, Y., Volkow, N. D., & Howes, O. D. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0135 · Cited by 330
An intensive outpatient approach for cocaine abuse treatment
Rawson, R. A., Shoptaw, S. J., Obert, J. L., McCann, M. J., Hasson, A. L., Marinelli-Casey, P. J., Brethen, P. R., & Ling, W. (1995) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(94)00080-b · Cited by 197 · cited 2×
“In brief, Matrix Model is a framework for patients with stimulant-use disorder in which the therapist functions as both a teacher and a coach, encouraging a positive relationship with the patient to reinforce behavior change toward achieving abstinence and improving self-esteem/self-worth.”
MethodKatoh, R., Asano, T., Ueda, H., Morishita, R., Takeuchi, I. K., Inaguma, Y., & Kato, K. (2002) · The FASEB Journal · doi:10.1096/fj.02-0143fje · Cited by 193 · cited 1×
“In animal studies, riluzole stimulated BDNF synthesis in cultured astrocytes (Mizuta et al., 2001) enhanced expression of BDNF in the hippocampus (Katoh-Semba et al., 2002) and exerted antidepressant- and anxiolytic-like effects associated with increased hippocampal BDNF (Gourley et al., 2012).”
BackgroundRiluzole in the Treatment of Mood and Anxiety Disorders
Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G. (2008) · CNS Drugs · doi:10.2165/00023210-200822090-00004 · Cited by 177 · cited 3×
“…of neuropsychiatric conditions has yielded promising results which are mainly attributed to the complex glutamergic regulatory effects of riluzole in the CNS, and several other proposed effects which were mostly investigated through in vitro studies (Pittenger et al., 2008; Zarate and Manji, 2008).”
BackgroundInfluentialBrennan, B. P., Hudson, J. I., Jensen, J. E., McCarthy, J., Roberts, J. L., Prescot, A. P., Cohen, B. M., Pope, H. G., Renshaw, P. F., & Öngür, D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.191 · Cited by 168
Mizuta, I., Ohta, M., Ohta, K., Nishimura, M., Mizuta, E., & Kuno, S. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02098-5 · Cited by 145 · cited 1×
“In animal studies, riluzole stimulated BDNF synthesis in cultured astrocytes (Mizuta et al., 2001) enhanced expression of BDNF in the hippocampus (Katoh-Semba et al., 2002) and exerted antidepressant- and anxiolytic-like effects associated with increased hippocampal BDNF (Gourley et al., 2012).”
BackgroundGrant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84 · cited 2×
“…io n Ra ti ng S ca le w hi ch in cl ud ed s ev en m ea su re m en ts in cl ud in g ba se lin e vi si t an d ev en w ee ks . an eight-week RCT of patients with methamphetamine dependence, 14 participants received N-acetylcysteine plus naltrexone and 17 others received placebo (Grant et al., 2010a).”
Background
Cited by
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
de Boer, J. N., Vingerhoets, C., Hirdes, M., McAlonan, G. M., Amelsvoort, T. V., & Zinkstok, J. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.06.020 · Cited by 38
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13
“Acceptance and Commitment Therapy vs CBT [81] More CBT sessions over fewer sessions, and CBT over self-help booklet with the exception of self-help booklet outperforming 1-session of CBT [27, 87, 88] • Variation in outcome results between ACT and CBT with no difference in harms [81] Other behavioural interventions (n…”
Background
Metadata
- Authors
- Farahzadi, M.-H., Moazen-Zadeh, E., Razaghi, E., Zarrindast, M.-R., Bidaki, R., & Akhondzadeh, S.
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2018-12-11
- Volume
- 33
- Issue
- 3
- Pages
- 305-315
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2904633851
- Cited by
- 18
- References
- 12
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. https://app.cochat.ai/papers/10.1177/0269881118817166
- The paper
- Farahzadi, M.-H., Moazen-Zadeh, E., Razaghi, E., Zarrindast, M.-R., Bidaki, R., & Akhondzadeh, S. (2019). Riluzole for treatment of men with methamphetamine dependence: A randomized, double-blind, placebo-controlled clinical trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881118817166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.